🔎 Trials Near Me

Home › Lupus Nephritis › Pennsylvania

Pag-aaral pangklinika para sa Lupus Nephritis sa Pennsylvania

6 pag-aaral para sa Lupus Nephritis ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.

Mga Lungsod sa Pennsylvania

Opisyal na teksto ng pag-aaral (English)

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • Children's Hospital of Philadelphia - Accepting Young Adult and Adolescent Patients, Philadelphia
Nagre-recruitPhase 1/2
Edad 12 hanggang 65 · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT06121297

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 1/2
Edad 10 hanggang 29 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06839976

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

  • Fox Chase Cancer Center- Temple BMT, Philadelphia
Nagre-recruitPhase 2
Edad 16 hanggang 70 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07328581

VIBRANT: VIB4920 for Active Lupus Nephritis

  • Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
  • Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05201469

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

  • Rheumatic Disease Associates, Ltd., Willow Grove
Nagre-recruitPhase 4
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT07611214

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  • Jefferson Einstein Hospital Philadelphia, Philadelphia
Nagre-recruitPhase 1
Edad 12 hanggang 70 · Lahat ng kasarian · Na-update May 22, 2026 · NCT06308978

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.